Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

190.35 -2.10 (-1.09%)
Streaming Delayed Price Updated: 11:51 AM EDT, Jul 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
81 82 Next >
3 Spinoff Stocks You Should Buy Now: July 2024
Spinoff stocks often take time to gain their footing in the market giving investors an opportunity to get in early. 
Via InvestorPlace
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
These companies stand out for their pedigrees, robust financials, and future growth prospects. 
Via The Motley Fool
3 Dividend Growth Stocks to Buy and Hold
What's better than a dividend? A dividend that's growing. 
Via The Motley Fool
3 High-Yield Dividend Stocks That Still Look Like Bargains
The prices of these reliable dividend payers haven't kept pace with the frothy stock market. 
Via The Motley Fool
AbbVie Appeals To Supreme Court Over Attorney-Client Privilege In 'Long-Standing' AndroGel Case
AbbVie petitions the U.S. Supreme Court to protect its corporate records, arguing a lower court ruling threatens attorney-client privilege. 
Via Benzinga
AbbVie Unusual Options Activity
Via Benzinga
$1000 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
Via Benzinga
A Closer Look at AbbVie's Options Market Dynamics
Via Benzinga
Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on drug prices due to market consolidation. This trend raises critical... 
Via Benzinga
Topics Cannabis
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024 
Via MarketBeat
The 7 Best Warren Buffett Stocks to Buy in July 2024
Some investors may say value investing is dead, but its never a bad time to look at some of the best Warren Buffett stocks to buy 
Via InvestorPlace
A Glimpse Into The Expert Outlook On AbbVie Through 7 Analysts
Via Benzinga
Looking At AbbVie's Recent Unusual Options Activity
Via Benzinga
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
Healthcare stocks continue to lag the market up about 6% YTD, helped by Large Cap Biopharma but hurt by United Health. 
Via Talk Markets
The Smartest Dividend Stocks to Buy With $250 Right Now
$250 will go a long way with these great dividend stocks. 
Via The Motley Fool
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs. 
Via Benzinga
Topics ETFs
MarketBeat Week in Review – 7/1 - 7/5
The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season 
Via MarketBeat
Topics Economy
AbbVie Stock: A Perfect Dip for Investors to Buy
ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors 
Via MarketBeat
Topics ETFs
New Golden Investment: Universal Health Realty Income Trust
A Golden Investment is one in which I have fully recovered my entire investment either through dividends or from partial liquidation or a combination of both. 
Via Talk Markets
7 Dividend Aristocrats That Will Have Investors in High-Yield Heaven
These Dividend Aristocrats all have payouts yielding three times or more the average yield of the S&P 500. 
Via InvestorPlace
Topics Stocks
3 Under-the-Radar Biotech Stocks With Blockbuster Potential
Are you looking to boost your portfolio with the best under-the-radar biotech stocks? Here are the top three. 
Via InvestorPlace
3 Retirement All-Stars for Steady Growth and Income
Retirement stocks lead the pack with steady dividends and strong growth potential. Invest smartly for a worry-free retirement. 
Via InvestorPlace
Topics Retirement
Cash Flow Alert: 3 Stocks That Just Raised Their Dividends
These dividend growth stocks all have a long history of double-digit dividend increases and just announced another. 
Via InvestorPlace
2 High-Yielding Healthcare Stocks to Buy With $1,000 in July
These reliable dividend payers are no-brainer buys right now. 
Via The Motley Fool
3 Magnificent Stocks Retirees Can Buy and Hold Forever
These stocks could be ideal for investors in their golden years. 
Via The Motley Fool
Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn’t Discovered Yet
Undiscovered small-cap stocks hold the greatest potential for creating investor wealth as they can take off at a moment's notice. 
Via InvestorPlace
7 Dividend Kings to Buy With Your Roth IRA Money in 2024
These seven Dividend Kings offer reliable income streams and long-term growth potential, making them ideal holdings for your Roth IRA. 
Via InvestorPlace
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy. 
Via Benzinga
Can AbbVie Stock Keep Outpacing the S&P 500?
AbbVie has been a surprisingly strong performer of late. Can the stock keep it up? 
Via The Motley Fool
Topics Stocks
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
81 82 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.